In a world grappling with the evolving variants of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), another emerging respiratory virus, respiratory syncytial virus …

As the world continues to confront severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), respiratory syncytial virus (RSV) is also causing severe respiratory illness in millions …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the
causal agent of COVID-19 and stands at the center of the current global human pandemic …

In 2020, the emerging threat to humanity posed by the rapidly evolving COVID-19 pandemic
called for accelerated development of vaccines at unprecedented speeds. While far less …

In 2020, two mRNA-based vaccines, encoding the full length of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) spike protein, have been introduced for control of …

The emergence of highly transmissible severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) variants of concern (VOCs) that are resistant to the current COVID-19 …

The continual emergence of new severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants challenges available SARS-CoV-2 vaccines for adequate control of …

A broadly protective vaccine for COVID-19 is needed to end the pandemic and to prevent its
future recurrence. While the first-generation, spike-based vaccines are effective against …

The highly pathogenic coronaviruses SARS-CoV-2 and SARS-CoV have led to the COVID-
19 pandemic and SARS outbreak, respectively. The receptor-binding domain (RBD) of the …

Abstract mRNA technologies have recently proven clinical efficacy against coronavirus
disease 2019 and are among the most promising technologies to address the current …